Dual targeting of EGFR and ErbB3 most effectively blocked p-Erk and p-Akt in the presence of EGFR ligands and HRG, which translated into synergistic inhibition of tumor growth in A549 (Figure 5c) and H322 (Figure 5d). The gene discussed is AKT1; the disease is neoplasm.